FindTrial
Sign In

Cabozantinib tablets

DRUG3 trials

Sponsors

Exelixis

Conditions

CancerHepatocellular CarcinomaNSCLCRenal Cell CarcinomaSolid Tumors

Phase 1

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
CompletedNCT01553656
ExelixisCancer, NSCLC, Solid Tumors
Start: 2011-02-28End: 2015-07-31Target: 85Updated: 2015-08-20

Phase 3

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
CompletedNCT01865747
ExelixisRenal Cell Carcinoma
Start: 2013-06-30End: 2021-01-15Updated: 2021-04-27
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
CompletedNCT01908426
ExelixisHepatocellular Carcinoma
Start: 2013-09-26End: 2021-01-12Updated: 2021-05-06

Related Papers

Abstract 6370: Farnesyl transferase inhibitor KO-2806 enhances the antitumor activity of cabozantinib in ccRCC tumors that progress on anti-VEGFR agents
Cancer Research2025-04-21
RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment
Radiology Imaging Cancer2023-09-017 citations
Abstract 1943: Disparities in multinational phase III liver cancer clinical trials by regions of the world
Cancer Research2023-04-04
Authors’ reply to Bhattacharya
Cancer Research Statistics and Treatment2023-04-01
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
2023-01-035 citations
Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.
2022-04-266 citations
Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
BMC Cancer2022-04-0922 citations
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
Clinical Cancer Research2021-12-1622 citations
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
2021-11-041 citations
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
2021-10-0721 citations
Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
Cancer Medicine2021-09-097 citations
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
2021-08-0716 citations
Anchored matching-adjusted indirect comparison (MAIC) of regorafenib (REG) versus cabozantinib (CAB) in advanced hepatocellular carcinoma (HCC).
Journal of Clinical Oncology2021-05-202 citations
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
2021-04-0610 citations
Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients
International Journal of Urology2020-08-1227 citations
A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma.
Journal of Clinical Oncology2020-05-206 citations
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
ESMO Open2020-01-0182 citations
Metastasiertes Nierenzellkarzinom: Ist das Alter therapierelevant?
Kompass Onkologie2020-01-01
Metastasiertes Nierenzellkarzinom: Cabozantinib als Behandlungsoption für ältere Patienten
Kompass Onkologie2020-01-01
Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
Kidney Cancer2019-12-283 citations

40 more papers not shown